©2024 Stanford Medicine
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
Trial ID: NCT00932893
Purpose
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus
pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific
gene profile involving the ALK gene after failure of one previous chemotherapy regimen that
included one platinum drug.
Official Title
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus
Stanford Investigator(s)
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Heather Wakelee
Winston Chen and Phyllis Huang Professor
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by a central laboratory)
- must have had disease progression after only one prior chemotherapy and that regimen
but must have included one platinum drug
- tumors must be measurable
Exclusion Criteria:
- prior treatment with PF-02341066
- current treatment in another clinical trial
Intervention(s):
drug: PF-02341066
drug: Pemetrexed
drug: Docetaxel
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061